A double blind placebo controlled trial of medroxyprogesterone acetate (MPA) in cancer cachexia.
Patients with breast cancer treated with MPA often report an improvement in appetite. Similar appetite stimulation is seen in patients treated with some corticosteroids, but MPA has a potential advantage over these drugs in that it does not exert a catabolic effect. MPA (100 mg tds orally) has there...
Main Authors: | Downer, S., Joel, S., Allbright, A., Plant, H., Stubbs, L., Talbot, D., Slevin, M. |
---|---|
Format: | Online |
Language: | English |
Published: |
1993
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968469/ |
Similar Items
-
Medroxyprogesterone acetate (MPA) in advanced granulosa cell tumours of the ovary--a new therapeutic approach?
by: Malik, S. T., et al.
Published: (1991) -
Effects of medroxyprogesterone acetate (MPA) in activating progesterone receptor signaling in benign and cancer-associated fibroblasts of the endometrium
by: Chung, I., et al.
Published: (2017) -
An evaluation of high-dose medroxyprogesterone acetate (MPA) therapy in women with advanced breast cancer.
by: Johnson, J. R., et al.
Published: (1984) -
Medroxyprogesterone acetate levels among Kenyan women using depot medroxyprogesterone acetate in the FEM-PrEP trial☆☆☆
by: Nanda, Kavita, et al.
Published: (2016) -
Medroxyprogesterone Acetate (Provera) in the Treatment of Metastatic Renal Cancer*
by: Bloom, H. J. G.
Published: (1971)